{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:04:18Z","timestamp":1787025858641,"version":"build-2736575974"},"reference-count":25,"publisher":"Siapec Servizi Srl","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-756","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T10:23:03Z","timestamp":1662718983000},"page":"278-287","source":"Crossref","is-referenced-by-count":4,"title":["Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study"],"prefix":"10.32074","volume":"114","author":[{"given":"Paolo","family":"Bironzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Melocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trebeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Migliorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2022,9]]},"reference":[{"key":"10.32074\/1591-951X-756_ref1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. https:\/\/doi.org\/10.3322\/caac.21708","DOI":"10.3322\/caac.21708"},{"key":"10.32074\/1591-951X-756_ref2","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours - Thoracic Tumours. 5th Edition. Lyon: IARC 2021."},{"key":"10.32074\/1591-951X-756_ref3","doi-asserted-by":"crossref","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines Insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw 2021;19:254-266. https:\/\/doi.org\/10.6004\/jnccn.2021.0013","DOI":"10.6004\/jnccn.2021.0013"},{"key":"10.32074\/1591-951X-756_ref4","doi-asserted-by":"crossref","unstructured":"Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALKfusion gene in non-small-cell lung cancer. Nature 2007;448:561-566. https:\/\/doi.org\/10.1038\/nature05945","DOI":"10.1038\/nature05945"},{"key":"10.32074\/1591-951X-756_ref5","doi-asserted-by":"crossref","unstructured":"Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0802","DOI":"10.1158\/1078-0432.CCR-09-0802"},{"key":"10.32074\/1591-951X-756_ref6","doi-asserted-by":"crossref","unstructured":"Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394. https:\/\/doi.org\/10.1056\/NEJMoa1214886","DOI":"10.1056\/NEJMoa1214886"},{"key":"10.32074\/1591-951X-756_ref7","doi-asserted-by":"crossref","unstructured":"Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012;461:245-257. https:\/\/doi.org\/10.1007\/s00428-012-1281-4","DOI":"10.1007\/s00428-012-1281-4"},{"key":"10.32074\/1591-951X-756_ref8","doi-asserted-by":"crossref","unstructured":"Gobbini E, Galetta D, Tiseo M, et al. Molecular profiling in advanced non-small-cell lung cancer: an Italian observational prospective study. Lung Cancer 2017;111:30-37. https:\/\/doi.org\/10.1016\/j.lungcan.2017.06.009","DOI":"10.1016\/j.lungcan.2017.06.009"},{"key":"10.32074\/1591-951X-756_ref9","doi-asserted-by":"crossref","unstructured":"Letovanec I, Finns S, Zygoura P, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results for the European Thoracic Oncology Platform Lungscape project. J Thorac Oncol 2018;13:413-425. https:\/\/doi.org\/10.1016\/j.jtho.2017.11.117","DOI":"10.1016\/j.jtho.2017.11.117"},{"key":"10.32074\/1591-951X-756_ref10","doi-asserted-by":"crossref","unstructured":"Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 2015;21:3631-3639. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2683","DOI":"10.1158\/1078-0432.CCR-14-2683"},{"key":"10.32074\/1591-951X-756_ref11","doi-asserted-by":"crossref","unstructured":"Mok T, Peters S, Camidge DR, et al. Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study. J Thorac Oncol 2020:S1556-0864(20)30815-7. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.007","DOI":"10.1016\/j.jtho.2020.10.007"},{"key":"10.32074\/1591-951X-756_ref12","doi-asserted-by":"crossref","unstructured":"Zeng L, Li Y, Xu Q, et al. Comparison of next-generation sequencing and Ventana immunohistochemistry in detecting ALK rearrangements and predicting the efficacy of first-line Crizotinib in patients with advanced non-small cell lung cancer. Oncotargets and Therapy 2020;13:7101-7109. https:\/\/doi.org\/10.2147\/OTT.S265974","DOI":"10.2147\/OTT.S265974"},{"key":"10.32074\/1591-951X-756_ref13","doi-asserted-by":"crossref","unstructured":"Kalemkerian GP, Narula N, Kennedy EB, et. al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the Study of Lung Cancer\/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018;36:911-919. https:\/\/doi.org\/10.1200\/JCO.2017.76.7293. Epub 2018 Feb 5.","DOI":"10.1200\/JOP.18.00035"},{"key":"10.32074\/1591-951X-756_ref14","doi-asserted-by":"crossref","unstructured":"von Laffert M, Warth A, Penzel R, et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol 2014;9:1685-1692. https:\/\/doi.org\/10.1097\/JTO.0000000000000332","DOI":"10.1097\/JTO.0000000000000332"},{"key":"10.32074\/1591-951X-756_ref15","doi-asserted-by":"crossref","unstructured":"Lindeman NI, Cagle PT, Aisner DL, et al Updated molecular testing guideline for the selection of lung cancer patients for treatment with tyrosine kinase inhibitors: guidelines from the College of American Pathologist, the International Association for the Study of Lung Cancer, and the Association of Molecular Pathology. J Thorac Oncol 2018;13:323-358. https:\/\/doi.org\/10.1016\/j.jtho.2017.12.001","DOI":"10.1016\/j.jtho.2017.12.001"},{"key":"10.32074\/1591-951X-756_ref16","doi-asserted-by":"crossref","unstructured":"Marchetti A, Ardizzoni A, Papotti M, et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J Thorac Oncol 2013;8:352-358. https:\/\/doi.org\/10.1097\/JTO.0b013e31827d5280","DOI":"10.1097\/JTO.0b013e31827d5280"},{"key":"10.32074\/1591-951X-756_ref17","doi-asserted-by":"crossref","unstructured":"Blackhall FH, Peters S, Bubendorf L, et al., Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 2014;32:2780-2787. https:\/\/doi.org\/10.1200\/JCO.2013.54.5921","DOI":"10.1200\/JCO.2013.54.5921"},{"key":"10.32074\/1591-951X-756_ref18","doi-asserted-by":"crossref","unstructured":"Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6:774-780. https:\/\/doi.org\/10.1097\/JTO.0b013e31820cf053","DOI":"10.1097\/JTO.0b013e31820cf053"},{"key":"10.32074\/1591-951X-756_ref19","doi-asserted-by":"crossref","unstructured":"Monica V, Scagliotti GV, Ceppi P, et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009; 15:7547-7552. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1641","DOI":"10.1158\/1078-0432.CCR-09-1641"},{"key":"10.32074\/1591-951X-756_ref20","doi-asserted-by":"crossref","unstructured":"Shaw AT, Varghese AM, Solomon BJ, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 2013;24:59-66. https:\/\/doi.org\/10.1093\/annonc\/mds242","DOI":"10.1093\/annonc\/mds242"},{"key":"10.32074\/1591-951X-756_ref21","doi-asserted-by":"crossref","unstructured":"Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol 2016;27(suppl 5):v1-v27. https:\/\/doi.org\/10.1093\/annonc\/mdw326","DOI":"10.1093\/annonc\/mdw326"},{"key":"10.32074\/1591-951X-756_ref22","doi-asserted-by":"crossref","unstructured":"Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1(1):CD013453. https:\/\/doi.org\/0.1002\/14651858.CD013453.pub2","DOI":"10.1002\/14651858.CD013453.pub2"},{"key":"10.32074\/1591-951X-756_ref23","doi-asserted-by":"crossref","unstructured":"Thorne-Nuzzo T, Williams C, Catallini A, et al. A sensitive ALK immunohistochemistry companion diagnostic test identifies patients elegible for treatment with Crizotinib. J Thorac Oncol 2017;12:804-813. https:\/\/doi.org\/10.1016\/j.jtho.2017.01.020","DOI":"10.1016\/j.jtho.2017.01.020"},{"key":"10.32074\/1591-951X-756_ref24","doi-asserted-by":"crossref","unstructured":"Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol 2016;11:487-495. https:\/\/doi.org\/10.1016\/j.jtho.2015.12.111","DOI":"10.1016\/j.jtho.2015.12.111"},{"key":"10.32074\/1591-951X-756_ref25","doi-asserted-by":"crossref","unstructured":"Scagliotti GV, Parikh P, von Pawel J, et al. Phase III comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551. https:\/\/doi.org\/10.1200\/JCO.2007.15.0375","DOI":"10.1200\/JCO.2007.15.0375"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:26:56Z","timestamp":1730795216000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-756","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"article-number":"2"}}